T1	Participants 38 75	patients with advanced gastric cancer
T2	Participants 289 363	patients with non-resectable gastric and gastro-oesophageal adenocarcinoma
T3	Participants 365 529	Three hundred and sixty-nine patients with histological proof of adenocarcinoma, who had received no more than a single regimen of 5-fluorouracil-based chemotherapy
T4	Participants 2070 2085	cancer patients
